Abstract
For a long time, pharmacological therapy of allergic diseases such as asthma or rhinitis was mostly based on symptomatic treatment with corticosteroids, sympathomimetic drugs and anti-histamines. Due to the increased understanding of the basic mechanisms underlying the development of allergic diseases, several novel strategies have been expounded in the last years aiming to intervene directly in the relevant processes of the immunologic cascade. The first of such compounds reaching the market is now applicable in form of anti-IgE antibody (omalizumab) for treatment of severe allergic asthma, but due to the unique anti-allergic efficacy, other intriguing indications are more than likely. This review will summarize the basic mode of action and the pharmacodynamics of a treatment with anti-IgE and will discuss the current evidence.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
